Prognosis
Young Alzheimer's Patients Dealt a Blow by Medicare's Refusal to Cover Drug
Medicare’s proposed limits on access to Biogen’s Aduhelm cast shadow on treatment for the 200,000 patients in the U.S. under 65
Michele Hall, 54-years old, battling Alzheimer’s, received her first Aduhelm treatment last month.
Photographer: Zack Wittman/Bloomberg
This article is for subscribers only.
Jay Reinstein and Michele Hall wouldn't seem to most people like they would be in danger of suffering from a disease typically associated with aging.
Reinstein is just 60 years old, and Hall is 54. Both of them have young adult children. Yet both already struggle with driving, and they can no longer work because their minds don’t function as they once did.